Stocks to watch: From SpiceJet to Indian Oil Corporation, here are top stocks likely to be in action in Monday's trading session
Under the collaboration, Greenko ZeroC will be supplying carbon free energy and enable green hydrogen along with its various chemical derivatives
Pharmaceutical company Granules India Ltd reported an 80% surge in quarterly profit on Thursday, boosted by higher sales of painkiller drug Paracetamol
The Pharma benchmark has outperformed the overall market in recent trading sessions; sustenance above 200-DMA is likely to trigger further gains for it
Stocks to Watch Today: In the F&O space, Indiabulls Housing Finance, India Cements, PVR and RBL Bank are in the ban period on Monday
The analyst from HDFC Securities recommends buying Granules India 320 Call and simultaneously selling 340 Call of the September series.
Brokerage house Centrum Broking has given a 'buy' call for Vijaya Diagnostic Centre and Granules India stocks
IOL Chemicals slipped 10% to Rs 487, while Granules was down 8% to 285.80 on the BSE in intra-day trade
Jubilant Cadista is a fully-owned subsidiary of Cadista Holdings Inc, which is a part of the Noida-based Jubilant Life Sciences Company.
Drug firm Granules India on Tuesday reported an 8 per cent rise in its consolidated net profit to Rs 120 crore for the quarter ended June 30, 2021.
The stock of Tata Chemicals has maintained a good support base near Rs 690 levels and picked up momentum currently
Carlyle is expected to buy 42 per cent of promoter shares, which will trigger an open offer to acquire additional stake from others, CNBC TV18 report.
In Q2FY21, the company's Ebitda grew 78.6 per cent YoY, with a 935 basis points margin expansion YoY on changing product mix and improved operational efficiencies
Drug firm Granules India said it has received marketing approval from the US health regulator for Potassium Chloride extended release tablets, used for treatment of patients with hypokalemia
All that happened in the markets today
According to media reports, global private equity firms have expressed interest in acquiring a controlling stake in the company
The stock has rallied 86 per cent in the past three months as compared to 13.5 per cent rise in the S&P BSE Sensex
Analysts expect launches in formulations and additional capacity in pharmaceutical formulation intermediate (PFIs) to be key growth drivers
The stock hit a record high of Rs 350 today. It has surged 13% thus far in the current week, as compared to a 2% decline in the S&P BSE Sensex
As per the USFDA, the companies are recalling the product due to deviation from the current good manufacturing practices